Wake Forest University Health Sciences

Running trials

• Not yet recruiting

  Medical Mistrust Among Hispanic/Latino Gay, Bisexual and Other Men Who Have Sex With Men (HLMSM)

  NCT06132672· Wake Forest University Health Sciences· Source

• Not yet recruiting

  Opzelura Experience Study

  NCT07661979· Phase 4· Wake Forest University Health Sciences· Source

• Not yet recruiting

  The EDICT Trial - Therapy for Inflammatory Bowel Disease Flares

  NCT07143188· Wake Forest University Health Sciences· Source

• Not yet recruiting

  Tailoring TM-HTN Intervention for Black Patients

  NCT06593119· Wake Forest University Health Sciences· Source

• Recruiting

  Vibegron for ENergy Thinking and Resilience in Aging

  NCT06987383· Phase 3· Wake Forest University Health Sciences· Source

• Recruiting

  Study of GS-0415 and How It Works in People With HIV

  NCT07719491· Phase 1· Gilead Sciences· Source

• Recruiting

  RIsE Stroke Mobility Study

  NCT07638462· Wake Forest University Health Sciences· Source

• Enrolling by invitation

  System Interventions to Achieve Early and Equitable Transplants Study - Long-Term

  NCT07515794· Wake Forest University Health Sciences· Source

• Recruiting

  Enhancing Slow Wave Sleep in Depression

  NCT07143838· Wake Forest University Health Sciences· Source

• Recruiting

  BOOST: Blended Onsite and Offsite Structured Exercise Training and Coaching

  NCT07413198· Wake Forest University Health Sciences· Source

• Recruiting

  Telehealth and Remote Blood Pressure

  NCT07356518· Wake Forest University Health Sciences· Source

• Recruiting

  Culturally Tailored Program for Food-Insecure Adults: SPICE-D

  NCT07361341· Wake Forest University Health Sciences· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  NCT07351058· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

  NCT07096778· Phase 2· CellCentric Ltd.· Source

• Recruiting

  Evaluation of Flexible Conductive Hearing Aids

  NCT07222202· Wake Forest University Health Sciences· Source

• Recruiting

  Pyloric Sphincter Abnormalities in Patients With Gastroparesis Symptoms

  NCT04661215· Johns Hopkins Bloomberg School of Public Health· Source

• Recruiting

  This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

  NCT07290803· Sanofi· Source

• Recruiting

  Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

  NCT07061977· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  NCT07001748· Phase 2/3· ECOG-ACRIN Cancer Research Group· Source

• Recruiting

  OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

  NCT07136012· Phase 3· Amgen· Source

• Recruiting

  Sequential Multiple Assignment Randomized Trial to Reduce Food Insecurity

  NCT07031739· Wake Forest University Health Sciences· Source

• Recruiting

  Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

  NCT06484062· Phase 1· National Cancer Institute (NCI)· Source

• Recruiting

  A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

  NCT06661915· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Enhancing Physical Function in Older Adults With Chronic Kidney Disease

  NCT06738394· Wake Forest University Health Sciences· Source

• Recruiting

  Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

  NCT06860594· Phase 1· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Recruiting

  Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

  NCT06909565· Phase 4· Duke University· Source

• Active, not recruiting

  GLP-1s to Enhance Lasting Optimal Weight

  NCT06861439· Phase 4· Wake Forest University Health Sciences· Source

• Recruiting

  Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

  NCT06532279· Phase 2· NRG Oncology· Source

• Recruiting

  Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

  NCT06724237· Phase 3· Eastern Cooperative Oncology Group· Source

• Recruiting

  Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  NCT06317662· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  NCT06124157· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

  NCT06592924· Phase 3· Canadian Cancer Trials Group· Source

• Recruiting

  Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  NCT06672146· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

  NCT06401330· Phase 3· Children's Oncology Group· Source

• Recruiting

  Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

  NCT06287775· Phase 1/2· National Cancer Institute (NCI)· Source

• Recruiting

  DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

  NCT06805305· Phase 2· Diakonos Oncology Corporation· Source

• Active, not recruiting

  Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

  NCT06858839· Phase 3· Amgen· Source

• Recruiting

  Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

  NCT06513962· Phase 3· Children's Oncology Group· Source

• Recruiting

  Non-Invasive Preeclampsia Screening and Biobank

  NCT06643741· Sequenom, Inc.· Source

• Recruiting

  Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  NCT06418204· Wake Forest University Health Sciences· Source

• Recruiting

  Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

  NCT06736574· Phase 3· Cytokinetics· Source

• Recruiting

  RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE

  NCT06455085· University of Alabama at Birmingham· Source

• Active, not recruiting

  Remote Hypertension Management for Black Patients

  NCT06527794· Wake Forest University Health Sciences· Source

• Active, not recruiting

  Telehealth-Enhanced Assessment and Management

  NCT06247254· Wake Forest University Health Sciences· Source

• Recruiting

  Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

  NCT06337318· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.

  NCT06321601· Phase 3· Amgen· Source

• Recruiting

  A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

  NCT06368817· Phase 2· Children's Oncology Group· Source

• Recruiting

  A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study

  NCT06410209· Phase 2· Children's Oncology Group· Source

• Recruiting

  Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  NCT06317649· Phase 2· National Cancer Institute (NCI)· Source

Showing 50 of 250.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers26 recruiting
• Acute myeloid leukaemia10 recruiting
• Acute lymphoblastic leukaemia9 recruiting
• Ovarian cancer6 recruiting
• Colorectal cancer5 recruiting
• Lung cancer5 recruiting
• Coronary artery disease4 recruiting
• Glioblastoma4 recruiting
• Myelodysplastic syndromes4 recruiting
• Myeloproliferative neoplasms4 recruiting
• Atopic dermatitis (eczema)3 recruiting
• Down syndrome3 recruiting
• Follicular lymphoma3 recruiting
• Heart failure3 recruiting
• High blood pressure3 recruiting
• Kidney cancer3 recruiting
• Obesity3 recruiting
• Sarcoma3 recruiting
• Type 2 diabetes3 recruiting
• Alzheimer disease2 recruiting
• Chronic kidney disease2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Familial hypercholesterolaemia2 recruiting
• Head and neck cancer2 recruiting
• Hearing loss2 recruiting
• HIV2 recruiting
• Insomnia2 recruiting
• Melanoma2 recruiting
• Metastatic breast cancer2 recruiting
• Multiple myeloma2 recruiting
• Neuroblastoma2 recruiting
• Neuroendocrine tumours2 recruiting
• Prostate cancer2 recruiting
• Stroke2 recruiting
• Triple-negative breast cancer2 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Crohn's disease1 recruiting
• Depression1 recruiting
• Endometrial cancer1 recruiting
• Frontotemporal dementia1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Gastroparesis1 recruiting
• Haemophilia1 recruiting
• Meningioma1 recruiting
• Migraine1 recruiting
• Osteoporosis1 recruiting
• Sickle cell disease1 recruiting
• Thalassaemia1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Withdrawn

  Auditory Stimulation for Insomnia and Depression

  NCT07553364· Wake Forest University Health Sciences· Source

• Withdrawn

  Stromal Vascular Fraction (SVF) for Knee Post-Trauma Osteoarthritis (PTOA)

  NCT05515523· Early phase 1· Wake Forest University Health Sciences· Source

• Completed

  Validation of Chronic Obstructive Pulmonary Disease (COPD) Algorithm

  NCT07223749· Wake Forest University Health Sciences· Source

• Completed

  Emergency Medical Services (EMS) Telehealth to Speed STEMI Reperfusion

  NCT06945900· Wake Forest University Health Sciences· Source

• Withdrawn

  Adherence to Otezla

  NCT05601492· Early phase 1· Wake Forest University Health Sciences· Source

• Completed

  GrowWell - Responsive Bottle Feeding

  NCT06319807· Wake Forest University Health Sciences· Source

• Withdrawn

  Team Based Equity Conscious Telemedicine Approach to Hypertension

  NCT06424730· Wake Forest University Health Sciences· Source

• Completed

  Sleep Well 24 (SWELL24) Healthy Sleep-Wake Behaviors in Older Adults

  NCT05780983· Wake Forest University Health Sciences· Source

• Completed

  A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

  NCT06131398· Phase 1· Amgen· Source

• Completed

  The Bennett Kids PowerUP Project

  NCT05858580· Wake Forest University Health Sciences· Source

• Withdrawn

  Cereset Research For Chronic Nausea

  NCT05229107· Wake Forest University Health Sciences· Source

• Withdrawn

  WeArable Neuromodulation DeVice for the TrEatment of Alzheimer's Disease

  NCT05032482· Scion NeuroStim· Source

• Completed

  Facilitators and Barriers to the Clinical Implementation of MR-001

  NCT06003790· MedRhythms, Inc.· Source

• Completed

  Improving Glycemic Control Using a Virtual Weight Control Program and Continuous Glucose Monitoring

  NCT05935514· Pennington Biomedical Research Center· Source

• Completed

  Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis

  NCT05908240· University of Pennsylvania· Source

• Completed

  Telemedicine Management of Hypertension

  NCT05424744· Wake Forest University Health Sciences· Source

• Completed

  Rural Area Pharmacist Intervention for Diabetes

  NCT05761886· Wake Forest University Health Sciences· Source

• Completed

  Trial to Address Food Insecurity in Patients With Hypertension (SMART-FI)

  NCT05800145· Wake Forest University Health Sciences· Source

• Completed

  Tourette Discrimination (TD) Stigma Scale

  NCT05696769· Wake Forest University Health Sciences· Source

• Completed

  A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

  NCT05694260· Phase 2· Esperion Therapeutics, Inc.· Source

• Completed

  Transversus Abdominis Plane (TAP) Block Using Liposomal Bupivacaine in Metabolic and Bariatric Surgery Patients

  NCT05537883· Phase 1· Wake Forest University Health Sciences· Source

• Recruiting

  Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

  NCT05489887· Phase 2· Giselle Sholler· Source

• Completed

  Improving Disease Severity

  NCT05391178· Wake Forest University Health Sciences· Source

• Terminated

  Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

  NCT05353439· Phase 1· National Cancer Institute (NCI)· Source

• Completed

  System Interventions to Achieve Early and Equitable Transplants (STEPS) Study

  NCT05014256· Wake Forest University Health Sciences· Source

• Completed

  Appalachian Partnership to Reduce Disparities (Aim 2)

  NCT04378439· Wake Forest University Health Sciences· Source

• Completed

  Studying Heart Ablation After Left Atrial Closure in High-Bleeding-Risk Atrial Fibrillation Patients

  NCT07580937· University of Chicago· Source

• Completed

  Mapping the Natural History of Parenychymal and Cerebral Perfusion Changes in Acute Ischemic and Hemorrhagic Strokes

  NCT05865795· Wake Forest University Health Sciences· Source

• Completed

  SNIFF - Combo INI+EMPA Trial

  NCT05081219· Phase 2· Wake Forest University Health Sciences· Source

• Terminated

  Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)

  NCT04506086· Phase 4· Amgen· Source

• Terminated

  Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

  NCT04588246· Phase 3· NRG Oncology· Source

• Completed

  A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer

  NCT04702737· Phase 1· Amgen· Source

• Completed

  Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors

  NCT04469569· University of Alabama at Birmingham· Source

• Completed

  Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

  NCT03641313· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage

  NCT04088630· Early phase 1· Wake Forest University Health Sciences· Source

• Recruiting

  Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT04221542· Phase 1· Amgen· Source

• Completed

  Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

  NCT03484819· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

  NCT03887715· LivaNova· Source

• Completed

  Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer

  NCT03963739· Wake Forest University Health Sciences· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source

• Completed

  TRC-PAD Program: In-Clinic Trial-Ready Cohort

  NCT04004767· University of Southern California· Source

• Completed

  Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease

  NCT03696797· Wake Forest University Health Sciences· Source

• Terminated

  Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

  NCT03199885· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Testing Ramipril to Prevent Memory Loss in People With Glioblastoma

  NCT03475186· Phase 2· Wake Forest University Health Sciences· Source

• Completed

  Light Treatment Effectiveness (LITE) Study

  NCT03726489· University of Pennsylvania· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Boehringer Ingelheim· Source

• Terminated

  Histamine and Bone Pain Association in Participants With Breast Cancer Metastatic in the Bone

  NCT03529565· Wake Forest University Health Sciences· Source

• Completed

  Gastroparesis Registry 3

  NCT03680859· Johns Hopkins Bloomberg School of Public Health· Source

• Completed

  Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT03188432· Phase 2· Wake Forest University Health Sciences· Source

• Completed

  ATHN 7: Hemophilia Natural History Study

  NCT03619863· American Thrombosis and Hemostasis Network· Source

Showing 50 of 102.

Conditions

Diseases this institution publishes on or runs trials for.

• Alzheimer disease209 works · 11 trials
• Obesity147 works · 11 trials
• Psoriasis25 works · 6 trials
• Myeloproliferative neoplasms8 works · 7 trials
• Peripheral artery disease7 works · 1 trial
• Hidradenitis suppurativa7 works · 2 trials
• Alopecia areata5 works · 2 trials
• Tourette syndrome3 works · 1 trial